2017 Annual Meeting | C60 - Precision Neurology: The Promise and Perils of Personalized Medicine in the Genomic Era

Date Sunday 04/23/17

Time 03:30 PM - 05:30 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Peter K. Todd, MD, PhD, FAAN

Topic(s) General Neurology

Learning Objectives Participants will be aware of the different types of genetic testing tools available for clinical and research purposes, when to get these tests, and what to do with the information when they have it. They will also gain a greater understanding of how these tools might be used in the future for people with both genetically based neurological disorders and common neurological diseases. They will also learn about how disclosure of genetic results impacts patients and about how somatic mutations and repeat expansion contribute to the burden of neurological disease.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Case-based, Didactic, Interactive, Audience Participation

Event Timeline
03:30 PM - 03:35 PM	Luncheon	Introduction Peter K. Todd, MD, PhD, FAAN
03:35 PM - 04:05 PM	Speaker	What REVEAL and MedSeq Tell Us About the Future of Precision Medicine Kurt Christensen, PhD
04:05 PM - 04:35 PM	Speaker	Genetic Variance and Risk in Complex Neurological Disorders
04:35 PM - 05:00 PM	Speaker	We Are the 99%: How Non-exonic Sequences and Repeats Cause Neurological Disease Peter K. Todd, MD, PhD, FAAN
05:00 PM - 05:30 PM	Speaker	One Brain, Many Genomes: Somatic Mutations in Neural Development and Neurological Disease Christopher Walsh, MD, PhD

Faculty Disclosures
Peter K. Todd, MD, PhD, FAAN	Dr. Todd has received personal compensation in the range of $500-$4,999 for serving as a Consultant for REATA Therapeutics. Dr. Todd has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Legal services. Dr. Todd has stock in Denali Therapeutics. The institution of Dr. Todd has received research support from NIH. The institution of Dr. Todd has received research support from VA. The institution of Dr. Todd has received research support from Ann Arbor Against ALS. The institution of Dr. Todd has received research support from Packard Foudation. Dr. Todd has received intellectual property interests from a discovery or technology relating to health care. Dr. Todd has received publishing royalties from a publication relating to health care. Dr. Todd has received personal compensation in the range of $500-$4,999 for serving as a ANA Highlights module director with American Neurological Association.
Christopher Walsh, MD, PhD	Dr. Walsh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Maze therapeutics. Dr. Walsh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Third Rock Ventures. Dr. Walsh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Flagship Pioneering. Dr. Walsh has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of Neurology.
	No disclosure on file
Kurt Christensen, PhD	No disclosure on file

��ɫ��

��ɫ��